Opicinumab
Based on 1 Customer Validation
Opicinumab (BIIB033) is a human IgG1 monoclonal antibody targeting LINGO-1. Opicinumab binds LINGO-1 to block its negative regulatory signaling, suppress axonal degeneration, enhance axonal regeneration, promote remyelination, and exert neuroprotective effects. Opicinumab maintains axonal protective effects during co-administration with methylprednisolone. Opicinumab can be used for the research of multiple sclerosis, acute optic neuritis, and optic neuritis..
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.64%
- CAS No.: 1422268-07-2
- Masse moléculaire:145.2 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
|
LINGO-1 |
Opicinumab (BIIB033) (6 mg/kg; i.p.; once weekly; 3 doses) significantly reduces optic nerve axonal loss in Brown Norway rats with MOG-induced experimental autoimmune encephalomyelitis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Brown Norway rats (8-10-week-old female; MOG-induced experimental autoimmune encephalomyelitis)[3]
-
Dosage:6 mg/kg
-
Administration:i.p.; once weekly; 3 doses
-
Result:Exhibited a five-fold higher number of βIII tubulin-positive axons compared to control when administered alone with vehicle.
Exhibited an eight-fold higher number of βIII tubulin-positive axons compared to control when administered in combination with Methylprednisolone.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1422268-07-2
-
Appearance Liquid
-
Masse moléculaire 145.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Opicinumab]
-
Synonyms
BIIB033
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Tran JQ, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1(2):e18. Published 2014 Aug 21. [Content Brief]
[2]. Cadavid D, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189-199. [Content Brief]
[3]. Gresle MM, et al. Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. Mult Scler J Exp Transl Clin. 2016;2:2055217316641704. Published 2016 Apr 19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Opicinumab Related Classifications
HY-P99780 Related Classifications
Powered by Bioz